Severity
Moderate
FDA Drug recall · Reported November 24, 2021
cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.
Bayer Healthcare Pharmaceuticals Inc. recalled Tinactin (Tolnaftate 1%) LIQUID SPRAY NET WT150g (5.3 OZ) can, labeled as (a) Product of … - a moderate-severity action.
Tinactin (Tolnaftate 1%) LIQUID SPRAY NET WT150g (5.3 OZ) can, labeled as (a) Product of … was recalled by Bayer Healthcare Pharmaceuticals Inc. in November 24, 2021. Reason: cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzen…. Check the official notice for the remedy. Verify recall #D-0243-2022 with the FDA Drug before acting.
The recall
Bayer Healthcare Pharmaceuticals Inc. issued this moderate-severity FDA Drug recall-cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzen….
Sourced from official FDA Drug enforcement records. Verify recall #D-0243-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0243-2022) was formally reported on November 24, 2021, with the manufacturer initiating the action on October 1, 2021. It is classified under Moderate severity (Class II), with a current status of Terminated. Bayer Healthcare Pharmaceuticals Inc. is listed as the recalling firm, operating out of Whippany, NJ. Federal records list the affected scope as 4,990,860 cans.
The documented reason for this recall is: cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene. Distribution data in the federal record shows the product reached: Distributed Nationwide in the US, Puerto Rico, Canada and Mexico through a variety of retail channels.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
4,990,860 cans
Related Recalls
6
5 from same agency
Tinactin (Tolnaftate 1%) LIQUID SPRAY NET WT150g (5.3 OZ) can, labeled as (a) Product of Finland 20006101, (b) Product of Ireland 87022897, (c) Product of Ireland 87022897, with an instant redeemable coupon (IRC) tag attached to the can; Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, UPC 3 11017 41005 9, NDC 11523-0165-3 Tinactin (Tolnaftate 1%) LIQUID SPRAY NET WT150g (5.3 OZ) can, Labeled as (a) Product of Finland 20006101, (b) Product of Ireland 87022897, Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, UPC 3 11017 41005 9, NDC 11523-0165-3.
cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0243-2022 |
| Date reported | November 24, 2021 |
| Date initiated | October 1, 2021 |
| Recalling firm | Bayer Healthcare Pharmaceuticals Inc. |
| Firm location | Whippany, NJ |
| Affected scope | 4,990,860 cans |
| Distribution | Distributed Nationwide in the US, Puerto Rico, Canada and Mexico through a variety of retail channels. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 24, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.